JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-50
SponsorKasr El Aini Hospital
About this trial
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male adults aged 18 to 50 years with androgenetic alopecia.
Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
Willing and able to provide written informed consent.
Disqualifiers
Other types of hair loss, including inflammatory or scarring alopecia.
Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
Trial design
Design model
Single group
Treatments tested in this trial
Topical Minoxidil 5% Solution
DrugTopical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men will apply 1 cc twice daily and women will apply 1 cc once daily.
Scalp Punch Biopsy
Procedure/SurgeryThree 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment.
Tissue JAK2 Protein Measurement by ELISA
Diagnostic testTissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: Topical Minoxidil 5% With Scalp Biopsy and JAK2 AssessmentExperimental treatment 3 interventions
Trial outcomes
Primary outcomes
1
Baseline Difference in Tissue JAK2 Protein Levels Between Balding and Non-Balding Scalp
Comparison of tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained at baseline from the balding area (vertex) and the non-balding area (occipital scalp) of participants with androgenetic alopecia.
Time frame
BaselineSecondary outcomes
1
Change in Tissue JAK2 Protein Levels in Balding Scalp After 12 Weeks of Topical Minoxidil
Change in tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained from the balding scalp area at baseline and again after 12 weeks of topical minoxidil 5% treatment.
Time frame
Baseline to Week 122
Change in Trichoscopic Hair Parameters After 12 Weeks of Treatment
Change in trichoscopic parameters from baseline to Week 12, including hair density, terminal hair density, vellus hair density, average hair thickness, follicular unit density, percentage of single, double, and triple-or-more hairs per follicular unit, and average number of hairs per follicular unit.
Time frame
Baseline to Week 123
Correlation Between Change in Tissue JAK2 Levels and Clinical Response
Correlation between the change in tissue JAK2 protein levels after treatment and the degree of clinical improvement assessed by trichoscopic parameters and baseline clinical characteristics.
Time frame
Week 12Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov